Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Regulation Reimbursement

Obama on the Donut Hole Deal

This article was originally published in RPM Report

  • Analysis

Executive Summary

Here are the remarks by President Obama after a meeting with AARP CEO Barry Rand on June 22. It is noteworthy that Obama introduced the agreement with the senior lobbying group: the donut hole discount plan is a much easier sale politically as a benefit for seniors than as a deal with the drug industry. Obama, however, is careful to highlight that industry's willingness to come forward with a deal demonstrates that the challenges to reform are surmountable.

Table

View full table

Topics

Tags:
BioPharmaceutical Regulation Reimbursement
Latest Headlines

Brand Drug Shortages Complicate US FDA Messaging To Congress

Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks, Platform Principles Without Designation

FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why

See All
UsernamePublicRestriction

Register

PS080582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By